- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer | Clinical
Oritinib Shows Promise in EGFR T790M+ NSCLC
May 21, 2022
Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.
Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC
May 18, 2022
During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.
First-in-Human Data of BBT-176 in NSCLC to be Presented at IASLC WCLC 2022
May 13, 2022
Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.
Binimetinib/Erlotinib Shows Tolerability in EGFR- or KRAS-Mutated NSCLC
May 11, 2022
Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.
Sequencing Osimertinib in Patients With EGFR-Mutated NSCLC
April 15, 2022
Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.
Next Steps for Investigation of Mobocertinib for EGFR Exon 20+ NSCLC
April 14, 2022
Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.
Part 2: Barriers and Sequencing for Osimertinib in EGFR+ NSCLC
April 11, 2022
During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.
EGFR Tyrosine Kinase Inhibitors and SCLC Transformation
April 03, 2022
Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.
ABCP Regimen Shows OS Benefit in Secondline NSCLC With EGFR Sensitizing Mutations
March 15, 2022
In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.
Part 1: Using Adjuvant Chemotherapy for EGFR-Positive NSCLC
March 14, 2022
During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.